for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AstraZeneca plc

AZN.L

Latest Trade

8,191.00GBp

Change

-40.00(-0.49%)

Volume

1,630,389

Today's Range

8,098.00

 - 

8,261.00

52 Week Range

6,499.80

 - 

9,523.00

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
8,231.00
Open
8,250.00
Volume
1,630,389
3M AVG Volume
40.35
Today's High
8,261.00
Today's Low
8,098.00
52 Week High
9,523.00
52 Week Low
6,499.80
Shares Out (MIL)
1,549.15
Market Cap (MIL)
128,970.70
Forward P/E
21.35
Dividend (Yield %)
2.43

Next Event

AstraZeneca PLC at Societe Generale Flagship Conference

Latest Developments

更多

Hutchmed (China) Says Co And Astrazeneca Initiate Sachi Phase Iii Trial Of Orpathys And Tagrisso Combination In Certain Lung Cancer Patients In China

AstraZeneca Says Data Shows Its Treatment Cuts Risk of Symptomatic COVID-19 By 83% In Some Settings

AstraZeneca Says Lokelma Granted Fast Track Designation In The US

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AstraZeneca plc

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.

Industry

Biotechnology & Drugs

Contact Info

1 Francis Crick Avenue

CB2 0AA

United Kingdom

+44.20.73045000

https://www.astrazeneca.com/Home

Executive Leadership

Leif Johansson

Independent Non-Executive Chairman of the Board

Pascal Soriot

Chief Executive Officer, Executive Director

Aradhana Sarin

Chief Financial Officer, Executive Director

Jeffrey A. Pott

Chief Human Resource Officer, General Counsel

Katarina Ageborg

Executive Vice President - Sustainability, Chief Compliance Officer

Key Stats

1.90 mean rating - 30 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

22.1K

2019

24.4K

2020

26.6K

2021(E)

35.7K
EPS (USD)

2018

3.460

2019

3.500

2020

4.020

2021(E)

5.171
Price To Earnings (TTM)
87.22
Price To Sales (TTM)
5.22
Price To Book (MRQ)
4.31
Price To Cash Flow (TTM)
26.20
Total Debt To Equity (MRQ)
80.29
LT Debt To Equity (MRQ)
72.81
Return on Investment (TTM)
2.31
Return on Equity (TTM)
1.71

Latest News

Latest News

FACTBOX-Front runners in development of antibody drugs against COVID-19

AstraZeneca, Eli Lilly, Regeneron and GlaxoSmithKline are among the biggest pharmaceutical companies to have developed COVID-19 treatments using a class of drugs called monoclonal antibodies.

COVAX allocates 4.7 mln AstraZeneca COVID-19 vaccine doses to N.Korea

The global vaccine-sharing network COVAX has set aside 4.73 million doses of AstraZeneca Plc's COVID-19 shot for shipment to North Korea, one of the very few countries that haven't started vaccination, according to its allocation plan.

UPDATE 1-AstraZeneca examining impact of new COVID variant on vaccine, antibody cocktail

AstraZeneca said on Friday it was examining the impact of a new coronavirus variant that is spreading rapidly in South Africa on its vaccine and its antibody cocktail, adding it was hopeful its combination drug would retain efficacy.

China's BioKangtai begins first shipment of AstraZeneca's COVID-19 shot

AstraZeneca Plc's COVID-19 vaccine partner in China, Shenzhen Kangtai Biological Products (BioKangtai), has begun its first shipment of the shot, sending more than four million doses to Indonesia, BioKangtai said on Friday.

UPDATE 5-AstraZeneca's antibody cocktail helps prevent COVID-19 for at least 6 months

* AZD7442 offers 83% protection over 6 months vs 77% over 3 months

EU drug regulator eyeing approval of AstraZeneca antibody treatment in 2022

The European Medicines Agency (EMA) intends to conclude the approval process for AstraZeneca's antibody cocktail to prevent and treat COVID-19 at the start of next year, the regulator's head of vaccine strategy said on Thursday.

AstraZeneca antibody works to prevent, treat COVID-19 in longer-term studies

AstraZeneca said on Thursday its COVID-19 antibody drug cocktail cut the risk of contracting symptomatic illness by 83% in a long-term follow-up, while the therapy also cut the risk of symptoms worsening when given within three days of first symptoms.

AstraZeneca-Oxford COVID-19 vaccine supply hits two billion doses

Two billion doses of the AstraZeneca-Oxford University COVID-19 vaccine have been supplied worldwide, the Anglo-Swedish drugmaker and its partner said on Tuesday, in just under a year since its first approval.

UK Stocks-Factors to watch on Nov. 15

Britain's FTSE 100 index is seen opening lower on Monday, with futures down 0.10%. *ASTRAZENECA: Bahrain has approved the emergency use of AstraZeneca's anti-COVID drug Evusheld, the state news agency reported on Sunday *WIZZ AIR: Wizz Air Chief Executive Jozsef Varadi said...

UPDATE 2-AstraZeneca, commodity stocks drag down UK's FTSE 100

* Miners, oil stocks weigh after dollar dents commodity prices

UPDATE 4-AstraZeneca starts to make modest profit from COVID-19 vaccine

AstraZeneca said it would begin to earn a modest profit from its coronavirus vaccine as the world learns to live with the virus and the drugmaker is in talks with several countries about new orders for delivery next year.

AstraZeneca drags down UK's FTSE 100

UK's FTSE 100 index fell on Friday, dragged lower by drugmaker AstraZeneca following its profit miss, while commodity-linked stocks slipped as a stronger dollar dented metal and oil prices.

AstraZeneca makes over $1 bln in Q3 vaccine sales, small profit

AstraZeneca on Friday posted $1.05 billion in COVID-19 vaccine sales for the third quarter and the not-for-profit vaccine added one cent to profit in the period, while the company reiterated its forecasts for 2021.

UPDATE 4-AstraZeneca to set up division for vaccines and antibody therapies

* Move shows company sees future for COVID-19 vaccine beyond pandemic - analyst (Adds new analyst comment, detail on COVID-19 vaccine)

UPDATE 1-AstraZeneca's COVID-19 antibody cocktail clears first step for registration in Australia

AstraZeneca's antibody cocktail against COVID-19 received its first nod for registration in Australia, the country's medical regulatory body said on Tuesday.

AstraZeneca's COVID-19 cocktail clears first step for registration in Australia

Australia's medical regulator said on Tuesday it had granted provisional determination to AstraZeneca for its antibody cocktail, the first protective shot other than vaccines against the COVID-19.

UPDATE 1-AstraZeneca to transfer some drug rights to Covis Pharma in $270 mln deal

AstraZeneca said on Monday it will transfer global rights for respiratory medicines Eklira and Duaklir to Covis Pharma Group for $270 million, as the Anglo-Swedish drugmaker looks to offload its older portfolio of medicines.

UPDATE 2-EU starts real-time review of AstraZeneca COVID-19 antibody cocktail

* Treatment is first COVID preventative shot other than vaccines

EU begins real-time review of AstraZeneca COVID-19 antibody cocktail

The European Union's medicines regulator said on Thursday it has started a real-time review of AstraZeneca's antibody-based COVID-19 therapy after the combination medicine showed success in treating and preventing severe illness. (Reporting by Pushkala Aripaka in Bengaluru...

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up